Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
NCT04603651 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2023-10-02
Summary
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Conditions
Interventions
- DRUG
-
Bamlanivimab
Administered intravenously (IV).
Sponsors & Collaborators
-
AbCellera Biologics Inc.
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Contact Lilly at 1-800-LillyRx (1-800-545-5979) · Eli Lilly and Company
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study of LY3463251 in Healthy Participants
NCT03764774 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
NCT04425538 ·Status: COMPLETED ·Phase: PHASE2
-
Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)
NCT04723589 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Examine Anktiva for the Treatment of COVID-19.
NCT07123727 ·Status: RECRUITING ·Phase: PHASE2
-
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
NCT01724580 ·Status: APPROVED_FOR_MARKETING
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants
NCT06797375 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects
NCT00639678 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
NCT01842386 ·Status: COMPLETED ·Phase: PHASE1
-
Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
NCT01552681 ·Status: TERMINATED ·Phase: PHASE2
-
Immunocompromised Swiss Cohorts Based Trial Platform
NCT04805125 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease
NCT06413511 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of Two Formulations of Ixekizumab in Healthy Participants
NCT04259346 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
NCT04951323 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
NCT06268860 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Injections of LY3074828 in Healthy Participants
NCT03886948 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Abatacept in IgG4-Related Disease
NCT03669861 ·Status: COMPLETED ·Phase: PHASE2
-
Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
NCT05263505 ·Status: TERMINATED ·Phase: PHASE2
-
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
NCT06915766 ·Status: AVAILABLE
-
A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
NCT06438263 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
NCT05651880 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
NCT04493502 ·Status: COMPLETED ·Phase: PHASE2
-
A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
NCT05515601 ·Status: COMPLETED ·Phase: PHASE1
-
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)
NCT04927169 ·Status: TERMINATED ·Phase: PHASE2
-
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
NCT06868381 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
NCT04605926 ·Status: WITHDRAWN ·Phase: PHASE3